TOKYO, Aug. 20 /PRNewswire/ -- YAKULT HONSHA CO., LTD. announced on August 20 that its collaborative study on the incidence of acute diarrhea with the National Institute of Cholera and Enteric Diseases in Kolkata, India, showed that daily intake of "Yakult" is efficacious in reducing the incidence of diarrhea in young children.
An unprecedented large-scale study, involving 3,585 children residing in an urban slum community in Kolkata, was conducted. As a result, "Yakult" was shown to be efficacious in reducing the incidence of acute diarrhea in young children and the difference was statistically significant. The demonstration that the continued intake of "Yakult" is effective in improving the gastrointestinal symptoms of the general public strongly corroborates the significance of drinking "Yakult."
These results were published on the "Epidemiology and Infection" website and the ePub is available on PubMed.
YAKULT HONSHA is engaged in research on probiotics, which refer to living microorganisms that confer a benefit on the host (people, etc.) by improving the balance of intestinal flora. A representative probiotic strain is Lactobacillus casei strain Shirota (YIT9029), which, in addition to an intestinal regulation action, has been verified in many published papers to have immunoregulatory actions such as helping to suppress the recurrence of superficial bladder cancer and reduce allergy symptoms. Hereafter, YAKULT HONSHA will continue to actively promote research on utilizing the remarkable power of microorganisms for the benefit of people's health.
Overview of Study
The number of children aged 5 years and under that die annually throughout the world is 8.80 million, and the country that has the most deaths is India (approximately 1.83 million children per year). It is reported that diarrhea is the cause in 13% of the deaths in children aged 5 years and under in India (Black RE et al, Lancet. 2010. 375: 1969-1987).